Charcot-Marie-Tooth Disease Type 2E/1F Mutant Neurofilament Proteins Assemble into Neurofilaments

Overview

Journal Cytoskeleton (Hoboken)

Specialty Cell Biology

Date 2019 Oct 2

PMID 31574566

Citations 11

Authors

Elizabeth J Stone

Atsuko Uchida

Anthony Brown

Affiliations

Soon will be listed here.

Abstract

Charcot-Marie-Tooth disease Type 2E/1F (CMT2E/1F) is a peripheral neuropathy caused by mutations in neurofilament protein L (NFL), which is one of five neurofilament subunit proteins that co-assemble to form neurofilaments in vivo. Prior studies on cultured cells have shown that CMT2E/1F mutations disrupt neurofilament assembly and lead to protein aggregation, suggesting a possible disease mechanism. However, electron microscopy of axons in peripheral nerve biopsies from patients has revealed accumulations of neurofilament polymers of normal appearance and no evidence of protein aggregates. To reconcile these observations, we reexamined the assembly of seven CMT2E/1F NFL mutants in cultured cells. None of the mutants assembled into homopolymers in SW13vim- cells, but P8R, P22S, L268/269P, and P440/441L mutant NFL assembled into heteropolymers in the presence of neurofilament protein M (NFM) alone, and N98S, Q332/333P, and E396/397K mutant NFL assembled in the presence of NFM and peripherin. P8R, P22S, N98S, L268/269P, E396/397K, and P440/441L mutant NFL co-assembled into neurofilaments with endogenous NFL, NFM, and α-internexin in cultured neurons, although the N98S and E396/397K mutants showed reduced filament incorporation, and the Q332/333P mutant showed limited incorporation. We conclude that all the mutants are capable of assembling into neurofilaments, but for some of the mutants this was dependent on the identity of the other neurofilament proteins available for co-assembly, and most likely also their relative expression level. Thus, caution should be exercised when drawing conclusions about the assembly capacity of CMT2E/1F mutants based on transient transfections in cultured cells.

Citing Articles

Proteolysis-Based Biomarker Repertoire of the Neurofilament Proteome.

Petzold A J Neurochem. 2025; 169(3):e70023.

PMID: 40066701 PMC: 11894590. DOI: 10.1111/jnc.70023.

Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study.

Balajkova V, Prokopcova A, Elisak M, Mojzisova H, Pavelka K, Olejarova M Lupus Sci Med. 2025; 12(1.

PMID: 39832906 PMC: 11752028. DOI: 10.1136/lupus-2024-001309.

Haplotype editing with CRISPR/Cas9 as a therapeutic approach for dominant-negative missense mutations in .

Dua P, Simon B, Marley C, Feliciano C, Watry H, Steury D bioRxiv. 2025; .

PMID: 39763989 PMC: 11702708. DOI: 10.1101/2024.12.20.629813.

KIF5A regulates axonal repair and time-dependent axonal transport of SFPQ granules and mitochondria in human motor neurons.

Guerra San Juan I, Brunner J, Eggan K, Toonen R, Verhage M bioRxiv. 2024; .

PMID: 39314491 PMC: 11418931. DOI: 10.1101/2024.09.06.611684.

Customized antisense oligonucleotide-based therapy for neurofilament-associated Charcot-Marie-Tooth disease.

Medina J, Rebelo A, Danzi M, Jacobs E, Xu I, Ahrens K Brain. 2024; 147(12):4227-4239.

PMID: 39008620 PMC: 11629702. DOI: 10.1093/brain/awae225.

References

DiVincenzo C, Elzinga C, Medeiros A, Karbassi I, Jones J, Evans M . The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy. Mol Genet Genomic Med. 2015; 2(6):522-9. PMC: 4303222. DOI: 10.1002/mgg3.106. View

Suter U, Scherer S . Disease mechanisms in inherited neuropathies. Nat Rev Neurosci. 2003; 4(9):714-26. DOI: 10.1038/nrn1196. View

Holford L, Case P, Lawson S . Substance P, neurofilament, peripherin and SSEA4 immunocytochemistry of human dorsal root ganglion neurons obtained from post-mortem tissue: a quantitative morphometric analysis. J Neurocytol. 1994; 23(9):577-89. DOI: 10.1007/BF01262058. View

Bhagavati S, Maccabee P, Xu W . The neurofilament light chain gene (NEFL) mutation Pro22Ser can be associated with mixed axonal and demyelinating neuropathy. J Clin Neurosci. 2009; 16(6):830-1. DOI: 10.1016/j.jocn.2008.08.030. View

Doppler K, Kunstmann E, Kruger S, Sommer C . Painful Charcot-Marie-Tooth neuropathy type 2E/1F due to a novel NEFL mutation. Muscle Nerve. 2016; 55(5):752-755. DOI: 10.1002/mus.25410. View

Perrot R, Eyer J . Neuronal intermediate filaments and neurodegenerative disorders. Brain Res Bull. 2009; 80(4-5):282-95. DOI: 10.1016/j.brainresbull.2009.06.004. View

Berciano J, Peeters K, Garcia A, Lopez-Alburquerque T, Gallardo E, Hernandez-Fabian A . NEFL N98S mutation: another cause of dominant intermediate Charcot-Marie-Tooth disease with heterogeneous early-onset phenotype. J Neurol. 2015; 263(2):361-369. DOI: 10.1007/s00415-015-7985-z. View

Sainio M, Ylikallio E, Maenpaa L, Lahtela J, Mattila P, Auranen M . Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy. Neurol Genet. 2018; 4(3):e244. PMC: 5991776. DOI: 10.1212/NXG.0000000000000244. View

Lin K, Soong B, Yang C, Huang L, Chang M, Lee I . The mutational spectrum in a cohort of Charcot-Marie-Tooth disease type 2 among the Han Chinese in Taiwan. PLoS One. 2011; 6(12):e29393. PMC: 3242783. DOI: 10.1371/journal.pone.0029393. View

10.

Uchida A, Monsma P, Fenn J, Brown A . Live-cell imaging of neurofilament transport in cultured neurons. Methods Cell Biol. 2016; 131:21-90. PMC: 6007976. DOI: 10.1016/bs.mcb.2015.07.001. View

11.

Saporta M, Dang V, Volfson D, Zou B, Xie X, Adebola A . Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp Neurol. 2014; 263:190-9. PMC: 4262589. DOI: 10.1016/j.expneurol.2014.10.005. View

12.

Butinar D, Starr A, Zidar J, Koutsou P, Christodoulou K . Auditory nerve is affected in one of two different point mutations of the neurofilament light gene. Clin Neurophysiol. 2007; 119(2):367-75. PMC: 2266590. DOI: 10.1016/j.clinph.2007.10.004. View

13.

Nixon R, Shea T . Dynamics of neuronal intermediate filaments: a developmental perspective. Cell Motil Cytoskeleton. 1992; 22(2):81-91. DOI: 10.1002/cm.970220202. View

14.

Zidar J, Korosec M, Middleton L, Kyriakides T, Christodoulou K . A novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics. 2002; 4(2):93-6. DOI: 10.1007/s10048-002-0138-4. View

15.

Perez-Olle R, Jones S, Liem R . Phenotypic analysis of neurofilament light gene mutations linked to Charcot-Marie-Tooth disease in cell culture models. Hum Mol Genet. 2004; 13(19):2207-20. DOI: 10.1093/hmg/ddh236. View

16.

Berciano J, Garcia A, Peeters K, Gallardo E, De Vriendt E, Pelayo-Negro A . NEFL E396K mutation is associated with a novel dominant intermediate Charcot-Marie-Tooth disease phenotype. J Neurol. 2015; 262(5):1289-300. DOI: 10.1007/s00415-015-7709-4. View

17.

Perez-Olle R, Lopez-Toledano M, Goryunov D, Cabrera-Poch N, Stefanis L, Brown K . Mutations in the neurofilament light gene linked to Charcot-Marie-Tooth disease cause defects in transport. J Neurochem. 2005; 93(4):861-74. DOI: 10.1111/j.1471-4159.2005.03095.x. View

18.

Lee M, Xu Z, Wong P, Cleveland D . Neurofilaments are obligate heteropolymers in vivo. J Cell Biol. 1993; 122(6):1337-50. PMC: 2119859. DOI: 10.1083/jcb.122.6.1337. View

19.

Wang L, Ho C, Sun D, Liem R, Brown A . Rapid movement of axonal neurofilaments interrupted by prolonged pauses. Nat Cell Biol. 2000; 2(3):137-41. DOI: 10.1038/35004008. View

20.

Trojanowski J, Kelsten M, Lee V . Phosphate-dependent and independent neurofilament protein epitopes are expressed throughout the cell cycle in human medulloblastoma (D283 MED) cells. Am J Pathol. 1989; 135(4):747-58. PMC: 1880019. View